Michael acceptor peptidomimetics

Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-Pro-OH, "ZED1301"

5 mg 480 € available

Art. No. A108
Synonym ZED1301
Background info Peptidic inhibitor containing an electrophilic Michael acceptor (MA) warhead
Molecular Formula C53H77N9O14
Molecular Weight 1064.23
Purity by HPLC >95 % (214 nm)
Appearance Pale yellow solid
Solubility 3.50 mg/ml (3.28 mM) in PBS buffer
Alternative 10 μM in 0.1% (v/v) DMSO / aqueous buffers
Pre-dissolve e.g. 2.15 mg (2.02 μmol) in 202 μl DMSO - dilute e.g. 10 μl of that stock solution (10 mM) with 9990 μl aqueous buffer to obtain a 10 μM solution. DMSO stock solutions can be stored at -20°C for at least 6 months.
To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Application Site specific irreversible inhibitor of plasma transglutaminase (factor XIII, FXIII)
ZED1301 shows 30-fold selectivity for FXIII compared to tissue transglutaminase
IC50 = 100 nM (FXIII, using fluorescent Assay Substance A101[1])
IC50 = 3000 nM (TG2, using fluorescent Assay Substance A101[1])
[1] Oertel et al. Anal. Biochem. 2007, 367, 152.
Reference(s) Stieler, M. et al. Angewandte Chemie Intl. Ed. 2013, 52, 11930.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA